3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Neoplasm Metastasis
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Stomach Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
umbralisib
1
ublituximab
1
marizomib
1
fludarabine phosphate
1
fludarabine
1
enzastaurin
1
durvalumab
1
carotuximab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
Zoledronic Acid
1
Vitamin D
1
Receptors, Interleukin-6
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Interleukin 1 Receptor Antagonist Protein
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
Cisplatin
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease Progression
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts